Materias dentro de su búsqueda.
Mostrando 461 - 480 Resultados de 856 Para Buscar '"principal investigator"', tiempo de consulta: 2.26s Limitar resultados
  1. 461
    “…Primary sponsor: Daniel Blumberger (DMB), Principal Investigator Daniel.Blumberger@camh.ca, 416-535-8501 x 33662 Contact for public queries: DMB, Daniel.Blumberger@camh.ca Contact for scientific queries: ZJD, Zdaskalakis@health.ucsd.edu SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05730-7.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): study protocol for a randomized non-inferiority trial of magnetic seizure therapy versus electroconvulsive therapy
  2. 462
    “…The primary endpoint was survival without invasive mechanical ventilation to day 28 in the modified intention-to-treat population (mITT), comprising all randomised participants who received at least one dose of study drug under the documented supervision of the principal investigator or sub-investigator. Adverse events were assessed in all patients who received at least one dose of study drug. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
  3. 463
    “…TRIAL REGISTRATION: ChiCTR2100052862; http://www.chictr.org.cn, Principal investigator: MEN, Date of registration: 06/11/2021. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Median nerve block increases the success rate of radial artery cannulation in women with gestational hypertension undergoing cesarean section
  4. 464
    “…The study presented in this manuscript is funded by NIH National Institute on Minority Health and Health Disparities (NIMHD), Award # R01MD012761-01, Elizabeth Rink (Principal Investigator). The study’s ClinicalTrials.gov number is NCT03694418. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evidence of secular trends during the COVID-19 pandemic in a stepped wedge cluster randomized trial examining sexual and reproductive health outcomes among Indigenous youth
  5. 465
    “…Prof, Ablynx, Gilead, Regeneron, Roche, Abbott and MedImmune: Honoraria|Ablynx, Gilead, Regeneron, Roche, Abbott and MedImmune: principal investigator|Astra Zeneca, GSK, Pfizer Inc, Sanofi, MSD, Seqirus, Moderna, Novavax, Biofabri, and Janssen: Advisor/Consultant|Astra Zeneca, GSK, Pfizer Inc, Sanofi, MSD, Seqirus, Moderna, Novavax, Biofabri, and Janssen: Board Member|Astra Zeneca, GSK, Pfizer Inc, Sanofi, MSD, Seqirus, Moderna, Novavax, Biofabri, and Janssen: Honoraria|Astra Zeneca, GSK, Pfizer Inc, Sanofi, MSD, Seqirus, Moderna, Novavax, Biofabri, and Janssen: speaker and investigator Courtney Lambeth, BS, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: employee|Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Stocks/Bonds Ziqiang Chen, PhD, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: employee|Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Stocks/Bonds Jessie Lumley, MA, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: employee|Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Stocks/Bonds David Johnson, MD, MPH, Sanofi: employee Marissa B. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1741. A Phase 4, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxelis™ in Healthy Children Previously Vaccinated With a 2-Dose Primary Infant Series of Either Vaxelis™ or Hexyon™ (V419-016)
  6. 466
    “…Lambey Nakwa, Merck & Co., Inc.: Principal Investigator, Research support. F. De Araujo Motta, Merck & Co., Inc.: Grant Investigator, Grant recipient. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1955. A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin vs. Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants ≤3 Months of Age
  7. 467
    por Odgis, Jacqueline A., Gallagher, Katie M., Suckiel, Sabrina A., Donohue, Katherine E., Ramos, Michelle A., Kelly, Nicole R., Bertier, Gabrielle, Blackburn, Christina, Brown, Kaitlyn, Fielding, Lena, Lopez, Jessenia, Aguiniga, Karla Lopez, Maria, Estefany, Rodriguez, Jessica E., Sebastin, Monisha, Teitelman, Nehama, Watnick, Dana, Yelton, Nicole M., Abhyankar, Avinash, Abul-Husn, Noura S., Baum, Aaron, Bauman, Laurie J., Beal, Jules C., Bloom, Toby, Cunningham-Rundles, Charlotte, Diaz, George A., Dolan, Siobhan, Ferket, Bart S., Jobanputra, Vaidehi, Kovatch, Patricia, McDonald, Thomas V., McGoldrick, Patricia E., Rhodes, Rosamond, Rinke, Michael L., Robinson, Mimsie, Rubinstein, Arye, Shulman, Lisa H., Stolte, Christian, Wolf, Steven M., Yozawitz, Elissa, Zinberg, Randi E., Greally, John M., Gelb, Bruce D., Horowitz, Carol R., Wasserstein, Melissa P., Kenny, Eimear E.
    Publicado 2021
    “…Registered on November 13, 2018 Trial Sponsor: Icahn School of Medicine at Mount Sinai Contact Name: Eimear Kenny, PhD (Principal Investigator) Address: Icahn School of Medicine at Mount Sinai, One Gustave L. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The NYCKidSeq project: study protocol for a randomized controlled trial incorporating genomics into the clinical care of diverse New York City children
  8. 468
    “…The novel primary endpoint, the Clinical Impression of Change in Severity© (CI-CS), accommodates the heterogenous clinical presentation of NPC, GM2, and A-T: at screening, the principal investigator appoints for each patient a primary anchor test (either the 8-m walk test (8MWT) or 9-hole peg test of the dominant hand (9HPT-D)) based on his/her unique clinical symptoms. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia
  9. 469
    por Senefeld, Jonathon W., Johnson, Patrick W., Kunze, Katie L., Bloch, Evan M., van Helmond, Noud, Golafshar, Michael A., Klassen, Stephen A., Klompas, Allan M., Sexton, Matthew A., Diaz Soto, Juan C., Grossman, Brenda J., Tobian, Aaron A. R., Goel, Ruchika, Wiggins, Chad C., Bruno, Katelyn A., van Buskirk, Camille M., Stubbs, James R., Winters, Jeffrey L., Casadevall, Arturo, Paneth, Nigel S., Shaz, Beth H., Petersen, Molly M., Sachais, Bruce S., Buras, Matthew R., Wieczorek, Mikolaj A., Russoniello, Benjamin, Dumont, Larry J., Baker, Sarah E., Vassallo, Ralph R., Shepherd, John R. A., Young, Pampee P., Verdun, Nicole C., Marks, Peter, Haley, N. Rebecca, Rea, Robert F., Katz, Louis, Herasevich, Vitaly, Waxman, Dan A., Whelan, Emily R., Bergman, Aviv, Clayburn, Andrew J., Grabowski, Mary Kathryn, Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Vogt, Matthew N. P., Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Buchholtz, Zachary A., Pletsch, Michaela C., Wright, Katherine, Greenshields, Joel T., Joyner, Michael J., Wright, R. Scott, Carter, Rickey E., Fairweather, DeLisa
    Publicado 2021
    “…METHODS AND FINDINGS: Mayo Clinic served as the central institutional review board for all participating facilities, and any US physician could participate as a local physician–principal investigator. Eligible patients were hospitalized, were aged 18 years or older, and had—or were at risk of progression to—severe or life-threatening COVID-19; eligible patients were enrolled through the EAP central website. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
  10. 470
    “…Informed consent will be obtained from all participants by the clinical research coordinator and principal investigator. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06014-4.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Brain activity and upper limb movement analysis in children with Down syndrome undergoing transcranial direct current stimulation combined with virtual reality training: study protocol for a randomized controlled trial
  11. 471
    “…Patients participating in the study will not be aware of the assignment to the intervention or control group. The principal investigator, health care personnel, data collectors, and those evaluating the outcome are aware of patient grouping. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial
  12. 472
    “…PRIMARY SPONSOR, PRINCIPAL INVESTIGATOR, AND LEAD INVESTIGATOR IN HEIDELBERG: Svenja Taubner is responsible for the design and conduct of MBT-CD intervention and feasibility and pilot study, preparation of protocol and revisions, and publication of study results. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Mentalization-based treatment for adolescents with conduct disorder (MBT-CD): protocol of a feasibility and pilot study
  13. 473
    por Ashraf, Sohaib, Ashraf, Shoaib, Akmal, Rutaba, Ashraf, Moneeb, Kalsoom, Larab, Maqsood, Aadil, Imran, Muhammad Ahmad, Farooq, Iqra, Ashraf, Sidra, Siddiqui, Uzma Nasim, Ghufran, Muhammad, Akram, Muhammad Kiwan, Majeed, Nighat, Rafique, Sundas, Habib, Zaigham, Shahab, Muhammad Sarmad, Akmal, Adeen, Shaukat, Zeeshan, Abdin, Zain ul, Khaqan, Ayesha, Arshad, Shahroze, Rehman Virk, Muhammad Abdul, Gul, Mehak, Awais, Abeer bin, Hassan, Muhammad, Khalid, Noman, Iqbal, Qurrat Ul Ain, Ahmad, Tausif, Akram, Muaaz, Muhammad, Ameer, Khalil, Musa, Aslam, Aneeq, Umer, Muhammad, Sherazi, Syed Sami Hussain, Safdar, Zartasha, Ahmad, Sohail, Bilal, Muhammad, Zahid, Muhammad Nauman, Koshak, Abdulrahman E., Hilal, Abubakar, Malik, Ahmad Azam, Iqbal, Usman, Baig, Atif Amin, Alahmadi, Yaser Masuod, Humayun, Ayesha, Malik, Amber, Ahmad, Ali, Ashraf, Muhammad, Saboor, Qazi Abdul, Izhar, Mateen
    Publicado 2021
    “…Data analysts will also be blinded to avoid conflict of interest. Site principal investigator will be responsible for ensuring masking. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prophylactic potential of honey and Nigella sativa L. against hospital and community-based SARS-CoV-2 spread: a structured summary of a study protocol for a randomised controlled trial
  14. 474
    “…DISCLOSURES: Florian Wagenlehner, MD, Achaogen: Advisory Board member, study participation|Astellas: Honoraria|AstraZeneca: Honoraria|AstraZeneca: Advisory Board member|Biomedical Advanced Research and Development Authority (BARDA): Grant/Research Support|Bionorica: Honoraria|Bionorica: Meeting/travel support, study participation|Deutsches Zentrum für Infektionsforschung (DZIF): Study participation|Enteris BioPharma: Study participation|Everest Medicines: Grant/Research Support|German S3 guideline Urinary tract infections: Board Member|Glaxo Smith Kline: Advisor/Consultant|Glaxo Smith Kline: Honoraria|Glaxo Smith Kline: Consulting fees, meeting/travel support, advisory board member, principal investigator in a GSK-sponsored study|Global Antibiotic Research and Development Partnership (GARDP Foundation): Grant/Research Support|Guidelines European Association of Urology: Infections in Urology: Board Member|Helperby Therapeutics: Study participation|Janssen: Honoraria|Janssen: Advisory Board member|Klosterfrau: Honoraria|LeoPharma: Advisory Board member|MerLion: Advisory Board member|MIP Pharma: Honoraria|MSD: Advisory Board member|OM Pharma/Vifor Pharma: Advisory Board member, study participation|OM-Pharma: Honoraria|Pfizer: Honoraria|Pfizer: Advisory Board member|RosenPharma: Advisory Board member|Shionogi: Advisory Board member, study participation|Speaker research group German research foundation (DFG) Bacterial Renal Infections and Defense (FOR 5427): Study participation|Spero Therapeutics: Advisor/Consultant|Spero Therapeutics: Consulting fees|University Hospital Giessen and Marburg GmbH, and Justus Liebig University, Germany: Employee|Venatorx Pharmaceuticals, Inc.: Advisor/Consultant|Venatorx Pharmaceuticals, Inc.: Grant/Research Support|Venatorx Pharmaceuticals, Inc.: Consulting fees, Advisory Board member Caroline R. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2837. Impact of Regulatory Guidelines on Therapeutic, Clinical, and Microbiological Success Rates in Uncomplicated Urinary Tract Infection: Results from a Two Phase 3 Randomized Controlled Trials of Oral Gepotidacin (EAGLE-2 and EAGLE-3)
  15. 475
    “…At the time that the TERRA study was conducted, he served as Principal Investigator in his role as Coordinator of the Leuven University Fertility Center. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study
  16. 476
    “…BLINDING (MASKING): Patients participating in the study will not be aware of the assignment to the intervention or control group. The principal investigator, health care personnel, data collectors, and those evaluating the outcome are aware of patient grouping. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of the efficacy and safety of recombinant erythropoietin on the improvement of hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial
  17. 477
    “…BLINDING (MASKING): The project's principal investigator (PI) is unblinded. However, the PI will not analyse the data and interpret the results. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial
  18. 478
    “…EDP1815 will be given as 2 capsules twice daily (1.6 x 10(11) cells) for up to 7 days with the option to extend up to 14 days at the discretion of the principal investigator or their delegate, if the patient is felt to be clinically responding to treatment, is tolerating treatment, and is judged to be likely to benefit from a longer treatment course. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial
  19. 479
    “…Thaden, MD, PhD, Resonantia Diagnostics, Inc: Advisor/Consultant Oscar Go, PhD, Janssen: Employee|Janssen: Stocks/Bonds Bart Spiessens, PhD, Janssen: Employee|Janssen: Stocks/Bonds Darren Abbanat, PhD, Janssen: Employee at the time of analysis Florian Wagenlehner, MD, Achaogen: Advisory Board member, study participation|Astellas: Honoraria|AstraZeneca: Honoraria|AstraZeneca: Advisory Board member|Biomedical Advanced Research and Development Authority (BARDA): Grant/Research Support|Bionorica: Honoraria|Bionorica: Meeting/travel support, study participation|Deutsches Zentrum für Infektionsforschung (DZIF): Study participation|Enteris BioPharma: Study participation|Everest Medicines: Grant/Research Support|German S3 guideline Urinary tract infections: Board Member|Glaxo Smith Kline: Advisor/Consultant|Glaxo Smith Kline: Honoraria|Glaxo Smith Kline: Consulting fees, meeting/travel support, advisory board member, principal investigator in a GSK-sponsored study|Global Antibiotic Research and Development Partnership (GARDP Foundation): Grant/Research Support|Guidelines European Association of Urology: Infections in Urology: Board Member|Helperby Therapeutics: Study participation|Janssen: Honoraria|Janssen: Advisory Board member|Klosterfrau: Honoraria|LeoPharma: Advisory Board member|MerLion: Advisory Board member|MIP Pharma: Honoraria|MSD: Advisory Board member|OM Pharma/Vifor Pharma: Advisory Board member, study participation|OM-Pharma: Honoraria|Pfizer: Honoraria|Pfizer: Advisory Board member|RosenPharma: Advisory Board member|Shionogi: Advisory Board member, study participation|Speaker research group German research foundation (DFG) Bacterial Renal Infections and Defense (FOR 5427): Study participation|Spero Therapeutics: Advisor/Consultant|Spero Therapeutics: Consulting fees|University Hospital Giessen and Marburg GmbH, and Justus Liebig University, Germany: Employee|Venatorx Pharmaceuticals, Inc.: Advisor/Consultant|Venatorx Pharmaceuticals, Inc.: Grant/Research Support|Venatorx Pharmaceuticals, Inc.: Consulting fees, Advisory Board member Tetsuya Matsumoto, MD; PhD, member of the international study steering committee for the E.mbrace study and reports payment: Board Member Marc Bonten, MD, PhD, chair of the international study steering committee for the E.mbrace study (Janssen Vaccines), with payments made to UMC Utrecht: Board Member Michal Sarnecki, MD, Janssen: Employee|Janssen: Stocks/Bonds Jan Poolman, PhD, Janssen: Employee|Janssen: Stocks/Bonds…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2465. O-serotype Distribution of Escherichia coli Causing Invasive Disease in Tertiary Care Hospital Patients
  20. 480
    “…Feldman received compensation for serving as a principal investigator and participating in the conduct of the trial. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids
Herramientas de búsqueda: RSS